JM

Jennifer Mcmahon

Partner at Seroba

Ireland

Overview 

Jennifer McMahon is a Partner at Seroba, specializing in venture capital investments in the lifesciences sector, with notable achievements in leading investments in companies like Deciphex and Palliare. She holds a diverse educational background including a Chartered Director Programme at the Institute of Directors and an MSc from UCD Michael Smurfit Graduate Business School. Jennifer's career highlights include serving as a Partner at Seroba, where she has successfully led investments in lifesciences startups and played key roles in companies like Deciphex and Palliare. Her educational background includes a Chartered Director Programme at the Institute of Directors and an MSc from UCD Michael Smurfit Graduate Business School.

Work Experience 

  • Partner

    2021 - Current

  • Principal

    2019 - 2021

  • Associate

    2016 - 2019

  • Senior Investment Analyst

    2014 - 2016

  • Investment Analyst

    2011 - 2014

    Seroba Life Sciences is a Venture Capital fund that invests in innovative, European, life science companies. We invest in early-stage start-ups through to the more mature, development-stage bioscience and medical device companies

  • Member Board of Directors

    2022

  • International Chair

    2021

    International Chair and Board Observer at Level 20

  • Board Member

    2021

Palliare is a manufacturer of surgical smoke evacuation and insufflation technologies.

Raised $8,000,000.00 from Seroba Life Sciences, SCM AD Ventures and Western Development Commission.

  • Committee Member

    2019

  • Committee Member

    2019

  • Board Observer

    2020

  • Member Board Of Directors

    2016

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before.

Raised $129,596,339.00 from SV Health Investors, Lumira Ventures, Aperture Venture Partners, Wanxiang America Healthcare Investments Group, OSF Ventures, Bioventures Investors, EQT Life Sciences, Skydeck and Seroba Life Sciences.

  • Board Observer

    2017 - 2019

  • Member Board Of Directors

    2015 - 2018

  • Business Development Advisor

    2011 - 2011

    As part of my MSc. Biotechnology & Business (Michael Smurfit Business School), I carried out an extensive feasibility analysis and subsequent Business Plan (2011-2014) development for a novel UCD spin-out company (Phision Therapeutics). This process involved an in-depth analysis of the ophthalmic market place in light of the anti-angiogenic compounds that are being developed by Phision Therapeutics and the formulation of an approriate business plan to suit the current market dynamics.

  • Post-Graduate Student: MSc. Biotechnology & Business at UCD.

    2010 - 2011

Articles About Jennifer

Relevant Websites